{"id":4325,"date":"2018-05-18T09:23:33","date_gmt":"2018-05-18T13:23:33","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4325"},"modified":"2018-05-18T09:23:33","modified_gmt":"2018-05-18T13:23:33","slug":"scholar-rock-holding-corporation","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/scholar-rock-holding-corporation\/","title":{"rendered":"Scholar Rock Holding Corporation"},"content":{"rendered":"<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/SRRK.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter size-full wp-image-4326\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/SRRK.jpg\" alt=\"SRRK\" width=\"288\" height=\"213\" \/><\/a><\/p>\n<p>Company: Scholar Rock Holding Corporation<br \/>\nSymbol: SRRK<br \/>\nDescription: They are a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.<br \/>\nTrade Date: 5\/24<br \/>\nShares: 5.36 million<br \/>\nPrice Range: $13.00-$15.00<br \/>\nUnderwriter(s): Jefferies, Cowen, BMO Capital<br \/>\nCo-Manager(s): Wedbush PacGrow<br \/>\nTerms Added: 5-14-18<\/p>\n<p><strong><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1727196\/000104746918003733\/a2235690zs-1a.htm\" target=\"_blank\">Link to Prospectus<\/a><\/strong><\/p>\n<p><strong><a href=\"http:\/\/www.retailroadshow.com\/wp\/roadshows.asp\" target=\"_blank\">Link to Retail Roadshow<\/a><\/strong><\/p>\n<p><strong>Business<\/strong>:\u00a0They have a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. They have three clinical-stage product candidates, one of which is anticipated to commence a Phase\u00a03 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. They believe that each of their product candidates has the potential to address multiple indications.<\/p>\n<p><strong>License Agreement(s): <\/strong>They have worldwide rights to their\u00a0proprietary platform and all of their\u00a0product candidates, with the exception of certain early-stage antibodies that specifically inhibit the activation of TGF<span style=\"font-family: SYMBOL;\">b<\/span>1 in the context of regulatory T cells, which they\u00a0licensed to Janssen Biotech,\u00a0Inc., or Janssen, a subsidiary of Johnson\u00a0&amp; Johnson.<\/p>\n<p><strong>Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n<p><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><span style=\"font-weight: 400;\">IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n<p><strong>Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0<a href=\"https:\/\/www.ipoboutique.com\/cgi\/ipo-track-record-summary-report.php\"><span style=\"font-weight: 400;\">track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here&#8217;s a<a href=\"http:\/\/www.ipoboutique.com\/blog\/?p=3655\"> 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique&#8217;s service.<\/p>\n<p><b>Indicate with confidence,\u00a0<\/b><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><b>SUBSCRIBE<\/b><\/a><b>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company: Scholar Rock Holding Corporation Symbol: SRRK Description: They are a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Trade Date: 5\/24 Shares: 5.36 million Price Range: $13.00-$15.00 Underwriter(s): Jefferies, Cowen, BMO Capital Co-Manager(s): Wedbush[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1512],"class_list":["post-4325","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-srrk"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4325"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4325\/revisions"}],"predecessor-version":[{"id":4327,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4325\/revisions\/4327"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}